Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASADENA
2023-504472-24-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Prasinezumab IV with Placebo IV (2 arms). Primary endpoint: Change in total MDS-UPDRS score (sum of Parts I, II and III) from baseline at Week 52. Planned start Mar 2024; status: authorised.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2023-504472-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504472-24-00.